Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
IXI.L
SELLREMOVEIXICO plc · Healthcare · United Kingdom · $25M · Avg Vol: $15K/d
IXICO provides neuroimaging clinical trial services. At a $19M market cap, it is too small, lacks liquidity, and does not possess the scale or pricing power of the large-scale CDMOs we target in our healthcare theme.
COMPANY DESCRIPTION
IXICO plc is a medical imaging advanced analytics company that provides AI-driven neuroimaging services to the global biopharmaceutical industry for clinical trials. The company's competitive moat is its proprietary algorithms that measure disease progression in neurological disorders such as Alzheimer's, Huntington's, and Parkinson's. IXICO operates as a highly specialized niche CRO (Contract Research Organization) partner, integrated into the drug development pipelines of major pharma companies.
FINANCIAL SUMMARY (USD)
| Year | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR |
|---|---|---|---|---|---|---|
| Revenue | — | 12M | 9M | 8M | 9M | -8.9% |
| EPS | 0.04 | 0.03 | -0.03 | -0.06 | — | -35.2% |
| Shares | — | 48M | 48M | 48M | 93M | +92.5% |
| Debt | — | 692,738 | 519,554 | 421,550 | 240,310 | -29.7% |
| Equity | — | 17M | 15M | 13M | 16M | -2.1% |
| Op CF | — | 2M | 405,440 | -2M | -1M | -78.8% |
| Inv CF | — | -3M | -3M | -506,129 | -1M | — |
| Fin CF | — | -153,047 | -209,433 | -179,897 | 5M | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of IXI.L are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| IXI.L | IXICO plc(you) | $25M | 29 | SELL |
| SBTX.L | SkinBioTherapeutics plc | $34M | 21 | SELL |
| POLB.L | Poolbeg Pharma PLC | $56M | 39 | HOLD |
| SAR.L | Sareum Holdings plc | $47M | 14 | STRONG SELL |
| APTA.L | Aptamer Group PLC | $28M | 3 | STRONG SELL |
| HEMO.L | Hemogenyx Pharmaceuticals Plc | $63M | 14 | STRONG SELL |
| IMM.L | ImmuPharma plc | $37M | 1 | STRONG SELL |
| AREC.L | Arecor Therapeutics plc | $34M | 59 | HOLD |
| 4BB.L | 4basebio PLC | $110M | 5 | STRONG SELL |
| SCLP.L | Scancell Holdings plc | $333M | 37 | HOLD |
Peer medians: ROE 1.2% · P/E 26.9x · Gross margin 51.4%